Priyanka Verma, PhDWashington University, St. Louis2022 MCM Pilot Study Award Targeting drug resistance in BRCA-mutant ovarian cancers by exploiting endogenous base damage Many ovarian cancers are caused by mutations in proteins that usually function to repair DNA damage. These cancer cells with accumulated DNA damage are targeted by PARP inhibitor therapies. Despite ovarian tumors showing […]
Read More
Sneha Saxena, PhDMassachusetts General Hospital2022 James A. Harting Scientific Scholar Award Targeting ovarian cancer by exploiting a novel type of replication stress induced by unprocessed uracil in DNA Despite decades of work to develop new treatments, the five-year survival of patients with advanced ovarian cancer is between 10-30 percent. Hence, there is a pressing need […]
Read More
Development of RAD51 degraders for ovarian cancer treatment PARP inhibitor drugs have had a major impact on the clinical treatment of ovarian cancer in recent years, but they do not work in all patients. Many tumors have genetic mutations that make the tumor unable to repair damage to its DNA. PARP inhibitors exploit this fact […]
Read More
Jean-Bernard Lazaro, PhDDana-Farber Cancer Institute Targeting DNA repair genes and the nucleolar proteome to increase cisplatin sensitivity in ovarian cancer Patients with ovarian cancer who are treated with cisplatin often develop resistance to the drug, as cisplatin acts by damaging cellular DNA, which in turn induces apoptosis. Repair of cisplatin-induced DNA damage by a few […]
Read More
Michael Goldberg, PhDDana-Farber Cancer Institute2014 Kirwin-Hinton Family Scholar Unraveling the role of ATR in DNA repair and ovarian cancer therapy The majority of cancer therapies attempt to kill tumor cells using drugs that are often toxic. Many patients relapse because residual cells can establish new drug-resistant tumors. Unlike traditional therapies, the immune system can adapt […]
Read More
Remi Buisson, PhDMassachusetts General Hospital Unraveling the role of ATR in DNA repair and ovarian cancer therapy Proteins involved in the surveillance of genomic integrity, including BRCA1, BRCA2, and PALB2, help detect damage to DNA in cells and ensure that repairs are made when needed. Cells with mutations in BRCA1, BRCA2, and PALB2 have been […]
Read More
Erin George, MDUniversity of Pennsylvania2016 Skacel Family Scholar Targeting the ATR/CHK1 pathway in high grade serous ovarian cancer with ATR inhibitors New treatments are needed for recurrent ovarian cancer, a subset of which is more aggressive than the original cancer and has no effective treatment. Aggressive recurrent cancers rely on DNA repair pathways, involving proteins […]
Read More
Dipanjan Chowdhury, PhDDana-Farber Cancer Institute OC130658: Noncoding RNAs as Prognostic and Predictive Biomarkers in BRCA 1/2-Mutated and Wildtype Epithelial Ovarian Cancer Patients with epithelial ovarian cancer that carry BRCA1 or BRCA2 mutations can successfully be treated with platinum chemotherapy and PARP inhibitors because the BRCA1/2 mutations cause a defect in DNA repair. This allows the […]
Read More
Adam Karpf, PhDUniversity of Nebraska Medical Center2018 Kirwin-Hinton Bridge Funding Award Rhno1 in High-Grade Serous Ovarian Cancer High-grade serous ovarian cancer (HGSOC) is the most common and deadly form of ovarian cancer, accounting for about 25,000 cases and 15,000 deaths in the United States every year. New and improved therapies are critically needed for HGSOC. […]
Read More
Toshi Taniguchi, MD, PhDFred Hutchinson Cancer Research Center Secondary Mutations of BRCA1/2 in BRCA 1/2 Mutated Ovarian Cancer with Primary Platinum Resistance Platinum compounds are key drugs for the treatment of ovarian cancer and often help patients gain initial remission. However, some patients do not respond, called “primary platinum resistance.” To understand why this happens, […]
Read More